BioSpace News Archive

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a study for treating triple-negative breast cancer with leronlimab in a humanized TNBC xenograft model.

IONIQ Sciences, Inc., is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare.

Caris Life Sciences® and ESSA Pharma Inc. announced a Precision Development program to support ESSA’s ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer failing current standard-of-care therapies.

BD, a leading global medical technology company, announced it has strengthened the U.S. government’s access to safety injection devices through increased manufacturing capacity and domestic supply.

Tonix Pharmaceuticals Holding Corp. , announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to participate in a panel discussion at the A.G.P. Fall Virtual Biotech & Specialty Pharma Conference on October 13, 2021.

Outlook Therapeutics, Inc. today announced that Suber S. Huang, MD, MBA, FASRS, Co-Founder and CEO of the Retina Center of Ohio, will present data from Outlook Therapeutics’ NORSE THREE supplemental safety study for ONS-5010 / LYTENAVA™

PolarityTE, Inc. today provided an update regarding its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers submitted to the Food and Drug Administration (FDA) in July 2021

Amgen (NASDAQ: AMGN) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™ (sotorasib).

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IRAK4 inhibitor, at the AACR-NCI-EORTC Virtual Conference.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data providing further evidence of bezuclastinib as a differentiated, potent, and selective KIT inhibitor.